Ken Pienta
Advanced in Bone Tumor

Dr. Ken Pienta

Oncology
Johns Hopkins Medicine
Skip Viragh Outpatient Cancer Center
Baltimore, MD 

Advanced in Bone Tumor
Johns Hopkins Medicine
Skip Viragh Outpatient Cancer Center
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Kenneth Pienta is the Donald S. Coffey Professor of Urology and a professor of oncology at the Johns Hopkins School of Medicine. He also holds an appointment in the department of pharmacology and molecular sciences. He is an internationally recognized leader in prostate cancer research and translational science. Dr. Pienta serves as the director of research for the Brady Urological Institute and co-leader of the Kimmel Cancer Center's Prostate Cancer Program. Dr. Pienta has a proven, peer-reviewed track record in organizing and administering a translational research program that successfully incorporates bench research, agent development and clinical application. He has international expertise in the development of novel chemotherapeutic programs for prostate cancer and has championed the concept that translational research is often best accomplished by multi-disciplinary teams of scientists and clinicians. Under his direction, the success of these endeavors led to the receipt of the first annual American Association for Cancer Research Team Science Award in 2007. Dr. Pienta received his B.A. in human biology from the Johns Hopkins University. He earned his M.D. from the Johns Hopkins School of Medicine. He completed his residency at the University of Chicago Hospitals and Clinics and performed a fellowship in oncology at The Johns Hopkins Hospital. Prior to joining Johns Hopkins, Dr. Pienta was the associate vice president for research, health sciences for the University of the Michigan from 2012 to 2013 and director of precision medicine for the Michigan Center for Translational Pathology from 2008 to 2013. He joined the Johns Hopkins faculty in 2013. Dr. Pienta's research interests include the ecology of cancer, tumor microenvironment, metastasis, biomarker development and novel therapeutic development. Dr. Pienta is a two-time American Cancer Society Clinical Research Professor Award recipient. He holds several patents, has authored more than 350 peer-reviewed articles and has been the principle investigator on numerous local and national clinical trials. Dr. Pienta is currently actively developing clinical trials and treating patients with newly diagnosed high risk and metastatic prostate cancer.

Dr. Pienta is rated as an Advanced provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Prostate Cancer, Bone Tumor, Familial Prostate Cancer, Prostatectomy, and Orchiectomy.

His clinical research consists of co-authoring 389 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 33 articles in the study of Bone Tumor.

Residency
University of Chicago Medicine, Internal Medicine, 1988
Specialties
Oncology
Licenses
Internal Medicine in MI
Board Certifications
American Board Of Internal Medicine
Fellowships
Johns Hopkins University School of Medicine, Oncology, 1991
Hospital Affiliations
The Johns Hopkins Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

Skip Viragh Outpatient Cancer Center
Viragh BLDG 5th FL, Baltimore, MD 21287
Call: 410-955-8964

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)
A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2024
Intervention Type: Drug, Radiation
Study Drug: Radium-223
Study Phase: Phase 2
A Phase II Study of Definitive Therapy for Newly Diagnosed Men With Oligometastatic Prostate Cancer After Prostatectomy
A Phase II Study of Definitive Therapy for Newly Diagnosed Men With Oligometastatic Prostate Cancer After Prostatectomy
Enrollment Status: Completed
Publish Date: February 16, 2023
Intervention Type: Drug, Radiation
Study Drugs: Leuprolide acetate, Docetaxel, Bicalutamide, Abiraterone Aacetate
Study Phase: Phase 2
A Phase 2 Study of Apalutamide in Active Surveillance Patients
A Phase 2 Study of Apalutamide in Active Surveillance Patients
Enrollment Status: Terminated
Publish Date: February 09, 2023
Intervention Type: Other, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
Enrollment Status: Terminated
Publish Date: October 15, 2021
Intervention Type: Drug
Study Phase: Phase 2
A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)
A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)
Enrollment Status: Completed
Publish Date: August 09, 2021
Intervention Type: Diagnostic test, Drug
Study Phase: Phase 2/Phase 3
Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men With Prostate Cancer
Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men With Prostate Cancer
Enrollment Status: Completed
Publish Date: May 07, 2020
Intervention Type: Drug
A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance
A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance
Enrollment Status: Withdrawn
Publish Date: March 22, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

386 Total Publications

Methods and Guidelines for Metabolism Studies: Applications to Cancer Research.
Methods and Guidelines for Metabolism Studies: Applications to Cancer Research.
Journal: International journal of molecular sciences
Published: July 16, 2025
View All 386 Publications
Similar Doctors
Christian F. Meyer
Distinguished in Bone Tumor
Dr. Christian F. Meyer
Oncology
Distinguished in Bone Tumor
Dr. Christian F. Meyer
Oncology

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
 (15.6 miles away)
410-955-8964
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Meyer will serve as the lead medical oncologist for adult sarcoma patients, and will focus on building the Adult Sarcoma and Connective Tissue Oncology Program. In collaboration with pediatric oncologist David Loeb, M.D., Ph.D., and orthopaedic surgeon Kristy Weber, M.D., Meyer will bring novel therapies to the clinic for sarcoma patients. Meyer received his bachelors and masters degrees in cell and molecular biology from Stanford University. From there, he joined the Medical Scientist Training Program at Baylor College of Medicine and earned his medical degree followed by a doctorate in immunology. Meyer completed his residency at the University of Maryland and served as chief resident in medicine from 2004-2005. Afterward, he joined our fellowship program in medical oncology and has been working in the laboratory of Jonathan Powell, M.D., Ph.D., on projects relating to the characterization of molecular regulatory pathways involved in T-cell activation and energy. As a third-year fellow, Meyer served as the chief fellow for our Training Programs in Hematology and Medical Oncology and he received a Young Investigator Award from the American Society of Clinical Oncology in 2010. Dr. Meyer is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Mesenchymoma, Undifferentiated Pleomorphic Sarcoma, Bone Tumor, and Ganglioneuroblastoma.

Daniel Lubelski
Distinguished in Bone Tumor
Dr. Daniel Lubelski
General Surgery | Oncology | Neurosurgery
Distinguished in Bone Tumor
Dr. Daniel Lubelski
General Surgery | Oncology | Neurosurgery

Johns Hopkins Outpatient Center

601 North Caroline Street, Floor 5, Floor 5, 
Baltimore, MD 
 (15.6 miles away)
410-955-6406
Languages Spoken:
English, Hebrew
See accepted insurances
Offers Telehealth

Daniel Lubelski is a fellowship-trained neurosurgeon with expertise in complex spine surgery and peripheral nerve surgery. He treats patients with spinal diseases and deformities, spine and nerve tumors, and brachial plexus injuries and other peripheral nerve injuries. Dr. Lubelski’s training in complex and robotic spine surgery, spinal oncology and peripheral nerve injuries allows him to comprehensively evaluate patients and develop custom treatment plans to address symptoms and improve patients’ quality of life. He prioritizes patient-centered care, effective communication and working in multidisciplinary collaboration to identify the best treatment. After obtaining his undergraduate degree at the City University of New York, Dr. Lubelski spent a year doing predoctoral research at the National Institutes of Health. He then obtained his medical degree from the Cleveland Clinic Lerner College of Medicine, and he performed stem cell tumor research as a Howard Hughes Medical Institute fellow. Dr. Lubelski went on to the Johns Hopkins University School of Medicine for a neurosurgery residency and an enfolded fellowship in peripheral nerve surgery. His postdoctoral training also included a fellowship in complex spine surgery and spinal oncology at Johns Hopkins, as well as a traveling fellowship with advanced training at the Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. Dr. Lubelski is a prolific researcher who focuses on patient quality of life and on using big data to develop individualized prediction models to determine optimal treatments tailored to each person. He has authored more than 200 peer-reviewed papers and numerous textbook chapters, has lectured nationally and internationally, and serves as a reviewer for the top neurosurgical journals. Dr. Lubelski is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Spinal Tumor, Chordoma, Spinal Stenosis, Spinal Fusion, and Laminectomy.

Distinguished in Bone Tumor
Dr. Dennis A. Priebat
Hematology Oncology | Oncology
Distinguished in Bone Tumor
Dr. Dennis A. Priebat
Hematology Oncology | Oncology
110 Irving St Nw, Suite 2a38, 
Washington, DC 
 (20.8 miles away)
202-877-2505
Languages Spoken:
English
See accepted insurances

Dennis Priebat is a Hematologist Oncology specialist and an Oncologist in Washington, Washington, D.c.. Dr. Priebat is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, and Rhabdomyosarcoma Embryonal.

VIEW MORE BONE TUMOR DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pienta's expertise for a condition
ConditionClose
  • Elite
  • Prostate Cancer
    Dr. Pienta is
    Elite
    . Learn about Prostate Cancer.
    See more Prostate Cancer experts
  • Distinguished
  • Prostatectomy
    Dr. Pienta is
    Distinguished
    . Learn about Prostatectomy.
    See more Prostatectomy experts
  • Advanced
  • Bladder Cancer
    Dr. Pienta is
    Advanced
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Bone Tumor
    Dr. Pienta is
    Advanced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Familial Prostate Cancer
    Dr. Pienta is
    Advanced
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Renal Cell Carcinoma (RCC)
    Dr. Pienta is
    Advanced
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • Experienced
  • Adult Soft Tissue Sarcoma
    Dr. Pienta is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Astrocytoma
    Dr. Pienta is
    Experienced
    . Learn about Astrocytoma.
    See more Astrocytoma experts
  • Bone Marrow Aspiration
    Dr. Pienta is
    Experienced
    . Learn about Bone Marrow Aspiration.
    See more Bone Marrow Aspiration experts
  • Breast Cancer
    Dr. Pienta is
    Experienced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Fibrosarcoma
    Dr. Pienta is
    Experienced
    . Learn about Fibrosarcoma.
    See more Fibrosarcoma experts
  • Glioblastoma
    Dr. Pienta is
    Experienced
    . Learn about Glioblastoma.
    See more Glioblastoma experts
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.